Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
0.3204
USD
|
+0.12%
|
|
-2.32%
|
-93.89%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
147.4
|
56.7
|
99.94
|
275.4
|
19.53
|
-
|
-
|
Enterprise Value (EV)
1 |
147.4
|
56.7
|
99.94
|
275.4
|
19.53
|
19.53
|
19.53
|
P/E ratio
|
-4.4
x
|
-1.3
x
|
-1.72
x
|
-4.16
x
|
-0.25
x
|
-0.3
x
|
-0.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
199
x
|
73.3
x
|
177
x
|
12.4
x
|
24.2
x
|
1.94
x
|
EV / Revenue
|
-
|
199
x
|
73.3
x
|
177
x
|
12.4
x
|
24.2
x
|
1.94
x
|
EV / EBITDA
|
-6,663,988
x
|
-1,330,548
x
|
-1,853,324
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-6.43
x
|
-
|
-2.29
x
|
-4.28
x
|
-0.2
x
|
-0.2
x
|
-0.22
x
|
FCF Yield
|
-15.6%
|
-
|
-43.6%
|
-23.4%
|
-490%
|
-498%
|
-456%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
12,927
|
13,005
|
31,827
|
52,563
|
60,965
|
-
|
-
|
Reference price
2 |
11.40
|
4.360
|
3.140
|
5.240
|
0.3204
|
0.3204
|
0.3204
|
Announcement Date
|
3/9/21
|
3/9/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.285
|
1.363
|
1.558
|
1.58
|
0.8066
|
10.06
|
EBITDA
|
-
|
-22.11
|
-42.61
|
-53.92
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-22.21
|
-43.62
|
-54.99
|
-67.12
|
-90.9
|
-88.49
|
-97.07
|
Operating Margin
|
-
|
-
|
-15,303.51%
|
-4,034.48%
|
-4,308.09%
|
-5,751.57%
|
-10,970.87%
|
-964.42%
|
Earnings before Tax (EBT)
1 |
-
|
-22.13
|
-43.51
|
-55.26
|
-62.62
|
-87.6
|
-86.43
|
-94.11
|
Net income
1 |
-
|
-22.13
|
-43.51
|
-55.28
|
-62.68
|
-87.61
|
-86.44
|
-94.11
|
Net margin
|
-
|
-
|
-15,267.72%
|
-4,055.61%
|
-4,023.11%
|
-5,543.44%
|
-10,716.12%
|
-935.05%
|
EPS
2 |
-2.370
|
-2.590
|
-3.350
|
-1.830
|
-1.260
|
-1.268
|
-1.056
|
-1.073
|
Free Cash Flow
1 |
-
|
-22.92
|
-
|
-43.55
|
-64.35
|
-95.71
|
-97.34
|
-88.98
|
FCF margin
|
-
|
-
|
-
|
-3,195.08%
|
-4,130.36%
|
-6,056.28%
|
-12,068.27%
|
-884.08%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/9/21
|
3/9/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.271
|
5.367
|
0.407
|
0.359
|
0.011
|
0.41
|
0.458
|
0.544
|
0.146
|
0.532
|
0.3462
|
0.3468
|
0.3624
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-14.55
|
-13.62
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.64
|
-7.026
|
-14.52
|
-14.83
|
-13.84
|
-17.31
|
-16.5
|
-16.83
|
-16.48
|
-23.52
|
-23.22
|
-22.61
|
-21.55
|
-9.5
|
-7.5
|
Operating Margin
|
-5,032.47%
|
-130.91%
|
-3,567.08%
|
-4,129.81%
|
-125,809.09%
|
-4,222.68%
|
-3,603.28%
|
-3,093.2%
|
-11,285.62%
|
-4,421.8%
|
-6,707.74%
|
-6,519.09%
|
-5,946.96%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.62
|
-7.012
|
-14.48
|
-14.77
|
-14.22
|
-16.24
|
-15.61
|
-15.64
|
-15.14
|
-22.44
|
-22.47
|
-21.92
|
-20.75
|
-9.5
|
-7.5
|
Net income
1 |
-13.62
|
-7.012
|
-14.48
|
-14.77
|
-14.24
|
-16.26
|
-15.62
|
-15.65
|
-15.16
|
-22.45
|
-22.47
|
-21.92
|
-20.75
|
-9.5
|
-7.5
|
Net margin
|
-5,024.72%
|
-130.65%
|
-3,558.72%
|
-4,113.09%
|
-129,409.09%
|
-3,964.63%
|
-3,410.04%
|
-2,877.02%
|
-10,380.82%
|
-4,220.3%
|
-6,490.87%
|
-6,320.59%
|
-5,726.05%
|
-
|
-
|
EPS
2 |
-1.050
|
-0.5400
|
-0.4300
|
-0.4000
|
-0.3600
|
-0.4400
|
-0.3600
|
-0.2700
|
-0.1900
|
-0.3500
|
-0.3280
|
-0.3100
|
-0.2840
|
-0.2300
|
-0.2100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/29/23
|
5/12/23
|
8/8/23
|
11/7/23
|
3/21/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-22.9
|
-
|
-43.5
|
-64.4
|
-95.7
|
-97.3
|
-89
|
ROE (net income / shareholders' equity)
|
-
|
-54.1%
|
-80%
|
-96.1%
|
-73.7%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-2.460
|
-1.990
|
-1.430
|
-1.270
|
-
|
-
|
-
|
Capex
1 |
-
|
1.78
|
3.39
|
0.16
|
1.05
|
1.45
|
0.8
|
0.83
|
Capex / Sales
|
-
|
-
|
1,187.72%
|
12.03%
|
67.2%
|
91.56%
|
99.26%
|
8.29%
|
Announcement Date
|
3/6/20
|
3/9/21
|
3/9/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
0.3204
USD Average target price
4.5
USD Spread / Average Target +1,304.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -93.89% | 19.53M | | +51.85% | 57.87B | | +40.97% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|